Tisotumab vedotin

Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575) . Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer[1][2][3].

Product Specifications

CAS Number

[1418731-10-8]

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tisotumab-vedotin.html

Purity

99.69

Solubility

10 mM in DMSO

Smiles

[Tisotumabvedotin]

Molecular Weight

152000 (average)

References & Citations

[1]Gray E, et al. Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell deathJournal for ImmunoTherapy of Cancer 2020;8.|[2]Alley S C, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro[J]. Cancer Research, 2019, 79 (13_Supplement) : 221-221.|[3]Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29 (2) :441-449. |[4]Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10 (22) :eadk1894.